Stock SEARL THE SEARLE COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials The Searle Company Limited

Equities

SEARL

PK0061701014

Pharmaceuticals

End-of-day quote Pakistan S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
57.04 PKR -0.40% Intraday chart for The Searle Company Limited -1.02% +10.80%
2023 Euro zone sovereign bond yields approach 8-month low ahead of US data RE
2023 The Searle Company Limited Announces Board Changes CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2024 2025
Capitalization 1 62,712 31,133 42,321 58,239 34,020 22,249 -
Enterprise Value (EV) 1 62,712 34,798 47,260 73,774 53,039 45,223 44,461
P/E ratio 23.3 x 13.9 x 16.9 x 15.4 x 14.5 x 22 x 10.1 x
Yield 1.47% 1.71% 1.25% 0.82% - - -
Capitalization / Revenue 3.82 x 1.72 x 2.07 x 2.22 x 1.14 x 0.5 x 0.44 x
EV / Revenue 3.82 x 1.93 x 2.31 x 2.81 x 1.77 x 1.03 x 0.87 x
EV / EBITDA 16.9 x 9.72 x 10.6 x 10.5 x 8.51 x 5.66 x 4.24 x
EV / FCF - -75.1 x -65.6 x 157 x - -5.69 x 53.9 x
FCF Yield - -1.33% -1.53% 0.64% - -17.6% 1.86%
Price to Book - 2.38 x 2.73 x 2.28 x 1.19 x 0.76 x 0.76 x
Nbr of stocks (in thousands) 345,191 345,191 345,191 390,066 390,066 390,066 -
Reference price 2 181.7 90.19 122.6 149.3 87.22 57.04 57.04
Announcement Date 10/12/18 10/1/19 9/29/20 10/4/21 10/3/22 - -
1PKR in Million2PKR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2024 2025
Net sales 1 16,396 18,062 20,475 26,220 29,910 44,082 50,945
EBITDA 1 3,714 3,579 4,466 7,017 6,236 7,996 10,498
EBIT 1 - 3,212 4,100 6,487 5,778 7,490 9,942
Operating Margin - 17.78% 20.02% 24.74% 19.32% 16.99% 19.52%
Earnings before Tax (EBT) 1 - 2,832 3,659 5,035 3,661 2,181 4,939
Net income 1 - 2,241 2,500 3,679 2,352 1,219 2,884
Net margin - 12.41% 12.21% 14.03% 7.86% 2.77% 5.66%
EPS 2 7.786 6.492 7.243 9.723 6.032 2.590 5.640
Free Cash Flow 1 - -463.4 -720.8 471.2 - -7,945 825
FCF margin - -2.57% -3.52% 1.8% - -18.02% 1.62%
FCF Conversion (EBITDA) - - - 6.72% - - 7.86%
FCF Conversion (Net income) - - - 12.81% - - 28.61%
Dividend per Share 2 2.676 1.538 1.538 1.231 - - -
Announcement Date 10/12/18 10/1/19 9/29/20 10/4/21 10/3/22 - -
1PKR in Million2PKR
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2024 2025
Net Debt 1 - 3,665 4,939 15,535 19,019 22,974 22,212
Net Cash position 1 - - - - - - -
Leverage (Debt/EBITDA) - 1.024 x 1.106 x 2.214 x 3.05 x 2.873 x 2.116 x
Free Cash Flow 1 - -463 -721 471 - -7,945 825
ROE (net income / shareholders' equity) 26.4% 18.6% 17.5% 17.9% 8.67% 3.7% 7.8%
ROA (Net income/ Total Assets) - - 10.8% - - - -
Assets 1 - - 23,190 - - - -
Book Value Per Share 2 - 37.90 44.90 65.60 73.50 75.20 74.90
Cash Flow per Share - - - - - - -
Capex 1 530 462 347 1,428 818 204 253
Capex / Sales 3.24% 2.56% 1.69% 5.45% 2.74% 0.46% 0.5%
Announcement Date 10/12/18 10/1/19 9/29/20 10/4/21 10/3/22 - -
1PKR in Million2PKR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
57.04 PKR
Average target price
65 PKR
Spread / Average Target
+13.96%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
THE SEARLE COMPANY LIMITED Stock The Searle Company Limited
+10.80% 79.9M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SEARL Stock
  4. Financials The Searle Company Limited